Conditions: Cancer
Keywords: Oncology Cancer Blood Cancers
Allocation: NON_RANDOMIZED | Intervention model: SINGLE_GROUP
Enrollment: 8
Healthy volunteers: no

Brief summary:
Phase 1 Open-label treatment with MPC-2130 for subjects with refractory cancer.

Detailed description:
MPC-2130 Phase 1 Clinical study was designed to evaluate its safety and pharmacokinetic profile in patients with advanced metastatic tumors or blood cancers as well as refractory cancers that progressed despite previous chemotherapy.

Arms:

Interventions: intervention 1: MPC-2130
Intervention descriptions: intervention 1: MPC-2130 10 mg/mL administered by intravenous infusion over 1-2 hours

Protocol document: